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Introduction
Gastrointestinal stromal tumors (GISTs) are mes-
enchymal tumors deriving from interstitial cells of 
Cajal in the gastrointestinal tract, mainly located in 
the stomach (60%), and small intestine.1 Since 
2000, GIST became targetable by new tyrosine-
kinase inhibitors (TKIs), given the role played by 
KIT and PDGFRA in its pathogenesis.2–4 In fact, 
around 85% of GISTs contain oncogenic muta-
tions in one of the two tyrosine-kinase receptor 
genes KIT or PDGFRA, and constitutive activa-
tion of either of these receptors has a central role in 
the pathogenesis of disease. Roughly 10–15% of 
GISTs, previously designated as wild-type GISTs, 
have no detectable mutations in KIT or PDGFRA, 
but might have genomic changes in other genes, 
such as SDH, NF1, or BRAF.5,6 Surgery is the 
mainstay of initial treatment and adjuvant imatinib 
is suggested in patients with a high risk of relapse.7–9 
Upon relapse, response and survival depend on the 
specific sensitivity to targeted treatment based on 
driver mutations. TKIs improved the prognosis of 
KIT-mutated patients and became the standard 
treatment in this cohort of patients. In this setting, 
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Abstract
Background: Rechallenge with imatinib is an option in advanced gastrointestinal stromal 
tumor (GIST) patients following progression with standard tyrosine-kinase inhibitors (TKIs), 
imatinib, sunitinib and regorafenib. We retrospectively collected data from metastatic Italian 
GIST patients treated with imatinib resumption after progression to conventional TKIs.
Methods: A total of 104 eligible advanced GIST patients, previously treated with imatinib, sunitinib 
and regorafenib, were collected from six referral Italian institutions. Mutational analysis was 
recorded and correlated with survival and response according to RECIST 1.1 or CHOI criteria.
Results: Overall, 71 patients treated with imatinib 400 mg as rechallenge were included. 
Mutational status was available in all patients. The median follow up was 13 months. In 
patients who received a rechallenge therapy, the median time to progression (TTP) was 
5.4 months [95% confidence interval (CI) 1.9–13.5] and overall survival (OS) was 10.6 months 
(95% CI 2.8–26.9). A correlation between mutational status, response rate, TTP and OS was not 
found but comparing deleted versus nondeleted KIT exon 11 patients, a significant difference 
was identified in terms of TTP and OS (p = 0.04 and p = 0.02, respectively).
Conclusions: Our retrospective data confirm that imatinib rechallenge is a reasonable option in 
advanced GIST. The prognostic value of the specific KIT mutations was confirmed in our series.
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the standard first-line therapy is imatinib mesylate, 
an oral multiple TKI, active against KIT, 
PDGFRA, ABL, and DDR.10 The recommended 
starting dose is 400 mg/day. Resistance to imatinib 
appears after a median time of 20–24 months in 
large series11,12 while in a substantial proportion of 
patients it is observed at 4 years, due to the acqui-
sition of additional mutations resulting in resistant 
KIT proteins.13,14 When resistance occurs, physi-
cians may choose to either escalate imatinib up to 
800 mg/day or start a second-line treatment.15 The 
standard second-line treatment after imatinib fail-
ure is sunitinib, although its benefit over placebo in 
terms of overall survival (OS) is relatively short, 
with numerous potentially serious side effects.9,16,17 
In the setting of imatinib failure, the phase III trial 
of sunitinib resulted in a median time to progres-
sion (TTP) of about 7 months, leading to the 
approval of sunitinib as the standard second-line 
therapy for GISTs.16 After the evidence of progres-
sive disease with imatinib and sunitinib, regorafenib 
represents the subsequent effective treatment, 
which demonstrated a better progression-free sur-
vival (PFS) compared with placebo. Regorafenib 
has been approved as third-line therapy based on 
the results of an international phase III trial, which 
documented significant improvement in PFS with 
regorafenib compared with placebo (4.8 versus 
0.9 months) after prior failure of at least imatinib 
and sunitinib.18 No further validated treatment 
options are available. A small randomized trial 
(RIGHT trial) showed that imatinib rechallenge 
after other TKIs, can improve PFS compared with 
placebo.19 This result can be explained by the fact 
that keeping on with a continuous kinase inhibi-
tion blocks tumor cells still sensitive to imatinib, 
until new resistant clones come out.
Currently, data on the use of imatinib rechallenge 
in daily clinical practice in metastatic GIST 
patients are not available and little is known about 
its impact on patients’ outcome.
Thus, we retrospectively collected data about 
metastatic GIST patients treated with imatinib 
rechallenge after progression with conventional 




A total of 71 eligible advanced GIST patients, 
previously treated with imatinib, sunitinib and 
regorafenib, at six Italian referral cancer centers 
(Campus Bio-Medico, Rome; Fondazione 
IRCCS Istituto Nazionale dei Tumori, Milan; 
IRCCS Candiolo-Fondazione del Piemonte per 
l’Oncologia, Candiolo; University of Bologna, 
Bologna; Azienda Ospedaliera Universitaria 
Careggi, Firenze; University of Palermo, Palermo) 
were included in the present analysis. All col-
lected patients were referred to these centers from 
October 2015 to October 2017. Our data were 
not reported in previous publications and there 
was no overlap between this population and those 
of other studies of our groups. All patients 
received all the three standard kinase inhibitors. 
Double dose of imatinib as active second line or 
as first line in exon 9 mutant GISTs was allowed. 
Mutational status was available in all patients; it 
was performed at the beginning of medical ther-
apy, therefore before starting imatinib (imatinib 
was the first therapy in all patients) and in 68 
patients, details about the type of mutation were 
available. Disease status was assessed according 
to standard practice every 12 weeks. Patients with 
oligo-progressing disease who had undergone 
surgical debulking in order to delay change of 
therapy, were included in the present analysis. 
Patients treated within clinical trials with new 
experimental therapies were excluded. 
Chemotherapy was not used in any patient. The 
population of patients was much selected and 
patients who received other agents before rechal-
lenge were excluded from the analysis.
The study protocol was approved by the ethics 
committee of Sant’Orsola Hospital, Bologna, 
Italy (No. 164/2017/O/Oss) as part of a large ret-
rospective analysis of patients with rare tumors. 
All patients provided written informed consent 
for inclusion in the study.
Statistical analysis
Descriptive analysis was made using median val-
ues and range. Differences between groups were 
assessed using the Chi-square test. TTP was cal-
culated as the period from the treatment start to 
the first evidence of disease progression. OS was 
calculated from the date of rechallenge until the 
date of death or the last documented time the 
patient was known to be alive. Patients with no 
evidence of progression were censored at the date 
of last tumor assessment.
Death was considered an event regardless of the 
cause. Patients alive or lost to follow up were 
B Vincenzi, M Nannini et al.
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censored at the last contact. Survival analysis was 
performed by the Kaplan–Meier product-limit 
method and the differences in term of TTP and 
OS according to the treatment received or the 
type of mutation detected were evaluated by the 
log-rank test. SPSS software (version 17.00, 
SPSS, Chicago, IL, USA) was used for statistical 




A total of 104 metastatic or advanced GIST 
patients collected from six referral Italian institu-
tions were included in the present retrospective 
analysis. A total of 10 of them were excluded 
because follow-up data were incomplete. Overall, 
six patients were excluded because of various rea-
sons (i.e. inclusion in clinical trial or treated with 
other off-label drugs). Therefore, 71 patients 
were considered fully evaluable. Patients charac-
teristics are summarized in Table 1. The median 
age was 63 years (range: 29–85). 39 patients 
(54.9%) were male and 32 (45.1%) were female.
A total of 63 of 72 patients had an Eastern 
Cooperative Oncology Group (ECOG) perfor-
mance score of 0 or 1. The site of the primary 
GIST was the stomach in 37 patients (52.1%), the 
small bowel in 23 (32.4%), and colon or rectum in 
11 (15.5%). The primary tumor was not deemed 
surgically amenable at the beginning of the treat-
ment course in 29 patients (40.8%). Overall, 59 
(83.1%) patients showed liver involvement, 42 
patients (59.2%) had more than two metastatic 
organs involved (liver and local infiltration of 
other organs or peritoneum), and 31 (43.7%) 
patients showed peritoneal involvement. A total of 
32 patients (45.1%) had received adjuvant 
imatinib and 19 patients (26.8%) had received 
imatinib (800 mg) as a second-line therapy.
All patients had received all the three standard 
kinase inhibitors active in this setting (imatinib, 
sunitinib and regorafenib). A double dose of 
imatinib as active second-line or as first-line treat-
ment in exon 9 mutant GISTs was allowed.
Response to imatinib rechallenge
Among all 71 patients treated with rechal-
lenge therapy, imatinib was administered at 
the standard dose of 400 mg daily in 59 (83 
%) patients, of which 19 (27 %) patients 
changed to a personalized schedule, such as 
reduced dose or discontinuous schedule. 12 
(17 %) patients received imatinib at a lower 
dose from the beginning.
The median follow up was 13 months (range 
1–42 months). The median TTP in this popula-
tion was 5.5 months [95% confidence interval 
(CI) 4.4–6.69]. OS was 11 months (95% CI 
6.83–16.71; Table 2 and Figure 1). The best 
response in our patients was partial response 
(PR), achieved in 5 (7%) patients, 32 (45%) 
patients had stable disease and 34 (48%) had dis-
ease progression (PD). Overall, 37 (52%) 
achieved a tumor control rate.
After progression to imatinib rechallenge, 18 
patients received further therapies: 9 (50%) 
patients were treated again with sunitinib (most 
of them with personalized schedules) and 9 (24%) 
patients were maintained on imatinib beyond 
documented progression.
Between patients who received post-imatinib rechal-
lenge, two patients out of nine treated with sunitinb 
achieved a PR and four patients a disease stabiliza-
tion lasting more than 3 months. In addition, three 
patients treated with imatinib beyond progression 
showed a disease stabilization lasting at least 3 
months; one of these is still on therapy 18 months 
after the documented radiological progression with-
out any additional locoregional therapy.
Mutational status and response to imatinib 
rechallenge
Exon 11 KIT-mutant GISTs were 62 (87.3%), 
but whole sequence details were available in 59 
patients (83.1%). Among the remaining nine 
patients, three carried an exon 9 KIT mutation, 
four patients were D842V PDGFRA mutant and 
two were KIT/PDGFRA wild-type. Of the latter, 
one patient was succinate dehydrogenase com-
plex iron sulfur subunit B (SDHB) deficient by 
immunohistochemistry while the other patients 
were SDHB positive.
The specific subtype of KIT exon 11 mutation 
was available in 54 patients: 24 (44.4%) harbored 
a KIT exon 11 deletion, while in 30 patients 
(56.6%) different exon 11 genomic aberrations 
were detected.
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Table 1. Patients’ features.
Number of patients % of patients
Sex (male) 39 54.9%
Sex (female) 32 45.1%
Age, years  
 Median 63 –
 Range 29–85 –
PS (ECOG 0 −1) 63 88.7%
Primary tumor  
 Stomach 37 52.1%
 Small bowel 23 32.4%
 Colon rectum 11 15.5%
Primary tumors not resected at diagnosis 29 40.8%
Liver involvement 59 83.1%
>2 disease sites 42 59.2%
Peritoneal involvement 31 43.7%
Adjuvant imatinib 32 45.1%
Second line with imatinib (800 mg) 19 26.8%
Patients with exon 11 mutation detected 62 87.3%
Patients with full mutational status 
details available
59 83.1%
Exon 11 mutated patients with full 
mutational status available
54  
 Deletion in exon 11 24 44.4%
 Other exon 11 mutation 30 55.6%
ECOG, Eastern Cooperative Oncology Group; PS, performance score.
According to the type of KIT exon 11 mutations, 
patients with exon 11 deletion showed a median 
TTP of 3.2 months (95% CI 1.98–4.02 months) 
versus 5.2 months (95% CI 2.9–8.3 months) of 
patients with other exon 11 mutations (p = 0.04). 
In terms of OS, patients with an exon 11 KIT 
deletion showed a median OS of 8 months (95% 
CI 4.61–9.33) versus 12 months (95% CI 9.67–
14.32 months; Table 3 and Figure 2).
Median TTP associated with the previous anti-
cancer therapy (regorafenib) was 7.1 months in 
our patients’ population, inferior but not far from 
the one recorded with imatinib rechallenge.
In addition, focusing on the PDGFRA mutant 
patients, three patients showed a prolonged dis-
ease stabilization (7, 15 and 20 months). In par-
ticular, one patient after 20 months is still on 
therapy with imatinib rechallenge without any evi-
dence of disease progression. Another patient after 
developing disease progression (TTP 15 months) 
was maintained on therapy with imatinib and is 
still alive with a cumulative OS of 28 months.
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Discussion
In metastatic KIT-mutant GIST patients, treat-
ment is mainly based on imatinib, to be contin-
ued until progression. The standard daily dosage 
of imatinib is 400 mg. This drug is usually well 
tolerated. Secondary resistance is the limiting fac-
tor to imatinib therapy long-term efficacy. This 
mechanism can be mainly due to the acquisition/
appearance of new molecular abnormalities asso-
ciated with the KIT and PDGFRA receptor sig-
nalling pathway, such as the acquisition of several 
different receptor mutations, the loss of KIT 
expression, the genomic amplification of KIT, the 
activation of an alternative downstream signalling 
pathways or to other mechanisms not related to 
KIT/PDGFRA receptors.20
Standard second-line therapy is sunitinib, a TKI-
inhibiting vascular endothelial growth factor recep-
tor (VEGFR) 1, 2, and 3 as well as KIT and 
PDGFRA, which showed to improve PFS in a ran-
domized trial versus placebo in patients failing 
imatinib treatment.21 Regorafenib, another TKI 
with activity on KIT, PDGFRA and VEGFR 1, 2 
and 3, showed to be effective in third-line therapy 
in patients, who underwent treatment with imatinib 
and sunitinib, as demonstrated in the GRID trial.18 
After these standard therapies, imatinib rechallenge 
was proposed as a valid option.
The hypothesis that some tumors were slowed 
down continuing the same TKI beyond progression 
came out from the fact that some patients in the 
Table 2. Outcome in patients who received imatinib rechallenge.
Survival data p-value
 Survival time 95% CI (months)
TTP 5.5 months 4.40–6.96 months  
OS 11 months 6.83–16.71 months  
Radiological response rate
Partial response 5 pts 7 % -
Stable disease 32 pts 45% -
Disease progression 34 pts 48 % -
CI, confidence interval; OS, overall survival; TTP, time to progression.
Figure 1. Time to progression in patients treated with imatinib rechallenge.
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GRID trial, going on with regorafenib, reached a 
post-progression PFS similar to the first one.
The suggestion that imatinib rechallenge could 
be effective was based on two observations. The 
first one is the finding, even if anecdotal, that 
imatinib interruption in patients with an imatinib-
refractory GIST-induced acute exacerbation or 
appearance of symptoms. The second one is the 
‘flare up’ phenomenon on 18F-fluorodeoxyglucose 
(FDG)-positron emission tomography (PET) 
imaging, consisting in a rapid upregulation of 
metabolic activity even within previously dormant 
tumor lesions.22,23 This phenomenon was 
observed in the context of a phase I/II clinical trial 
investigating the multi-targeted receptor TKI 
sunitinib. In this trial, patients with imatinib-
refractory GISTs stopped imatinib therapy prior 
to starting sunitinib. Several of these patients had 
a 18FDG-PET flair up few days following 
imatinib cessation. This finding implies that 
imatinib responsive tumor cell populations persist 
in these patients and that secondary resistance 
and disease progression most likely occurred in a 
distinctive clone with another mutation, which 
confers imatinib resistance.
These observations led to the hypothesis that 
even if progressive disease during other TKI 
treatments can be due to clones resistant to 
imatinib, other clones could be still sensitive, sup-
porting the rationale for imatinib rechallenge.
Results of the RIGHT trial confirmed these 
observations, showing an advantage in term of 
PFS with imatinib rechallenge compared with 
placebo (1.8 versus 0.9 months, respectively).19
As expected, our multicenter retrospective analy-
sis confirmed that imatinib rechallenge is widely 
used in Italian clinical practice. Of interest, TTP 
and OS reached in our series were longer than 
those observed in previous studies.
This new approach can be considered as a turn-
ing point with the traditional cancer treatment 
Table 3. TTP and OS according to type of KIT exon 11 mutation.

















CI, confidence interval; OS, overall survival; TTP, time to progression.
Figure 2. Time to progression and overall survival in patients with exon 11 deletions (purple) and exon 11 
other mutation (blue).
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strategy, which consists in the succession of dif-
ferent anticancer treatment options changed 
after the progression of the tumor without 
rechallenge to previous ones. With the spreading 
use of TKIs and the increasing recourse to sur-
gery, the concept of disease progression as well 
as that of the time to treatment-switch is chang-
ing and the rechallenge strategy can be located 
on this path.
In our series, a correlation between mutational 
status and response rate, TTP and OS was not 
found. On the contrary, exon 11 KIT-mutant 
GIST showed to be a prognostic factor also in our 
population. In particular, patients carrying a dele-
tion of KIT exon 11 displayed a shorter OS and 
TTP than patients carrying other KIT exon 11 
mutations.
These data confirmed that exon 11 KIT deletion 
is a negative prognostic factor. It was firstly 
described by Martin and colleagues as an inde-
pendent prognostic factor in primary localized 
GISTs and then confirmed by Kontogianni and 
colleagues.24–26 Moreover it was demonstrated by 
our group too in a retrospective analysis compar-
ing imatinib and sunitinib in second-line setting, 
where 11 KIT deletion compared with other exon 
mutations was identified as a negative prognostic 
factor for OS, in both treatment arms and to be 
associated with a shorter TTP.15
In conclusion, our retrospective data confirm that 
imatinib rechallenge is widely used in Italian clin-
ical practice and that it positively affects patient 
outcome, with an OS (10.6 months) and TTP 
(5.4 months) advantage superior to that observed 
in other studies. Therefore, imatinib rechallenge 
should be offered to all patients after failure of 
previous treatments.
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